| REVIEW ARTICLE |
|
| Year : 2021 | Volume
: 10
| Issue : 2 | Page : 69-71 |
|
|
Abametapir: A novel pediculicide with a unique mechanism
Suruchi Aditya1, Aditya Rattan2
1 Department and Institution-Senior Lecturer, Department of Pharmacology, Dr Harvansh Singh Judge Institute of Dental Sciences, Panjab University, Sector 25, Chandigarh, India
2 Department and Institution-Consultant Cardiologist, Heartline, SCO 60, Sector 6, Panchkula, Haryana, India
Correspondence Address:
Dr. Suruchi Aditya
Department of Pharmacology, Dr Harvansh Singh Judge Institute of Dental Sciences, Panjab University, Sector 25, Chandigarh
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/jdrntruhs.jdrntruhs_151_20
|
|
|
Pediculus humanus capitis or head louse, a blood-sucking, wingless arthropod, has been a source of repulsion and embarrassment causing social distress, parental anxiety, and absenteeism. The battle to eradicate this infestation has not been rewarding as the obligate parasite continues to produce resistance to effective first-line pediculicides such as permethrin. Abametapir is a new pediculicide that inhibits the metalloproteinases critical to the hatching process of the eggs. Being an ovicidal drug, it needs a single application. In two large phase 3 studies with 704 subjects aged ≥6 months, abametapir lotion eliminated lice in ≥80% of subjects after a single 10-min application with no nit combing. The common adverse effects observed are erythema, rash, and sensation of skin burning. The Food and Drug Administration approved abametapir lotion, 0.74%, for a one-time topical treatment of head louse infestation for patients aged 6 months and older in July 2020. Good efficacy, safety, and a novel mechanism of action make it a welcome addition to the list of effective lousicidal drugs.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
